Briefing · 2026-08-25
Q4 2026 readouts that matter
Five phase-3 primary completions the registry currently schedules for the fourth quarter, read through the evidence each program already carries.
Every date below is ClinicalTrials.gov's current primary-completion estimate, rendered live from the registry: if a sponsor moves a trial, this page moves with it. Primary completion is when data collection ends, not when results are announced; the announcement follows at the sponsor's timing.
The selection is editorial; the evidence grades are not. Each entry shows the design-quality grade the program's featured evidence already carries in this indication, with the reasoning on the asset page. Grades describe evidence quality, never investment merit, and nothing here is a prediction of any result.
NCT05202509 · Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease · ACTIVE_NOT_RECRUITING
NewAmsterdam Pharma's CETP inhibitor has so far been graded on LDL-lowering evidence, and this large outcomes-oriented phase 3 is the class's chance to show that the lipid effect carries through to clinical benefit. The existing graded evidence in this race is a large, quadruple-blind, placebo-controlled trial whose primary endpoint was LDL cholesterol; the step from a lipid endpoint to outcomes is exactly the inference the rubric's hard-endpoint rule exists to test.
NCT06894212 · A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia · RECRUITING
The TAAR1 agonist Sumitomo Pharma and Otsuka develop together (Otsuka sponsors this phase 3) is one of the few non-dopaminergic mechanisms with a live registrational program in schizophrenia. The graded evidence on file is two quadruple-masked, placebo-controlled trials on a symptom-score primary: one missed it and one was mixed. This next phase 3 decides whether the program can produce a confirmatory result in a field where placebo response has repeatedly sunk novel mechanisms.
NCT07494409 · A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia · RECRUITING
A program with an unusually disciplined design history: Kind Pharmaceuticals' HIF-PH inhibitor carries graded evidence from a masked, active-comparator trial against standard erythropoiesis-stimulating agents rather than placebo. The phase 3 completing this quarter extends that head-to-head posture; in renal anemia the comparator question is the commercial question.
NCT06962280 · A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight · ACTIVE_NOT_RECRUITING
The obesity race's largest franchise is extending into type 1 diabetes: SURPASS-T1D-2 enrolls an estimated 465 adults with type 1 diabetes and obesity or overweight, and its registered primary endpoint is the change in HbA1c at week 40, a glycaemic measure. Eli Lilly's existing graded evidence in obesity is a 2,539-participant double-blind, placebo-controlled trial graded strong on percent weight change; this readout tests a different population and a different endpoint.
NCT06617416 · A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC · RECRUITING
Included as the evidence-quality contrast: Akeso's PD-1/CTLA-4 bispecific enters this completion with graded evidence from a 44-participant, open-label, single-arm study, graded weak because the design cannot isolate the drug's own effect. A phase 3 completion is the moment a program either replaces that class of evidence with a controlled answer or does not; the grade that follows this readout will say more than the headline response rate.
Dates above move as sponsors update the registry, and this page moves with them. The full event universe, filterable by indication and phase, is on the readout calendar; each asset's complete evidence record, with every grade's reasoning, is one click through.